Physiology-based toxicokinetic modelling in the frame of the European Human Biomonitoring Initiative.


Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
05 2019
Historique:
received: 27 11 2018
revised: 25 01 2019
accepted: 28 01 2019
pubmed: 1 3 2019
medline: 3 1 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

Given the opportunities provided by internal dosimetry modelling in the interpretation of human biomonitoring (HBM) data, the assessment of the links between exposure to chemicals and observed HBM data can be effectively supported by PBTK modelling. This paper gives a comprehensive review of available human PBTK models for compounds selected as a priority by the European Human Biomonitoring Initiative (HBM4EU). We highlight their advantages and deficiencies and suggest steps for advanced internal dose modelling. The review of the available PBTK models highlighted the conceptual differences between older models compared to the ones developed recently, reflecting commensurate differences in research questions. Due to the lack of coordinated strategies for deriving useful biomonitoring data for toxicokinetic properties, significant problems in model parameterisation still remain; these are further increased by the lack of human toxicokinetic data due to ethics issues. Finally, questions arise as well as to the extent they are really representative of interindividual variability. QSARs for toxicokinetic properties is a complementary approach for PBTK model parameterisation, especially for data poor chemicals. This approach could be expanded to model chemico-biological interactions such as intestinal absorption and renal clearance; this could serve the development of more complex generic PBTK models that could be applied to newly derived chemicals. Another gap identified is the framework for mixture interaction terms among compounds that could eventually interact in metabolism. From the review it was concluded that efforts should be shifted toward the development of generic multi-compartmental and multi-route models, supported by targeted biomonitoring coupled with parameterisation by both QSAR approach and experimental (in-vivo and in-vitro) data for newly developed and data poor compounds.

Identifiants

pubmed: 30818231
pii: S0013-9351(19)30051-9
doi: 10.1016/j.envres.2019.01.045
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

216-230

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Dimosthenis A Sarigiannis (DA)

Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering Laboratory, University Campus, Thessaloniki 54124, Greece; HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, 10th km Thessaloniki-Thermi Road, 57001, Greece. Electronic address: denis@eng.auth.gr.

Spyros Karakitsios (S)

Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering Laboratory, University Campus, Thessaloniki 54124, Greece; HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, 10th km Thessaloniki-Thermi Road, 57001, Greece.

Elena Dominguez-Romero (E)

RECETOX, Masaryk University, Brno, Czech Republic.

Krystalia Papadaki (K)

Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering Laboratory, University Campus, Thessaloniki 54124, Greece.

Celine Brochot (C)

INERIS, France.

Vikas Kumar (V)

IISPV, Tarragona, Spain.

Marta Schuhmacher (M)

IISPV, Tarragona, Spain.

Moustapha Sy (M)

BfR, Berlin, Germany.

Hans Mielke (H)

BfR, Berlin, Germany.

Mathias Greiner (M)

BfR, Berlin, Germany.

Marcel Mengelers (M)

RIVM, Utrecht, the Netherlands.

Martin Scheringer (M)

RECETOX, Masaryk University, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH